Lepotex
Categoria
Lepotex Marchi, Lepotex Analoghi
Lepotex Marchi miscela
Lepotex Formula chimica
C18H19ClN4
Lepotex RX link
http://www.rxlist.com/cgi/generic3/clozapine.htm
Lepotex FDA foglio
Lepotex DMS (foglio di materiale di sicurezza)
Lepotex Sintesi di riferimento
Nessuna informazione disponibile
Lepotex Peso molecolare
326.823 g/mol
Lepotex Temperatura di fusione
183-184 oC
Lepotex H2O Solubilita
11,8 mg / L
Lepotex Stato
Solid
Lepotex LogP
2.502
Lepotex Forme di dosaggio
Compressa
Lepotex Indicazione
Per la gestione dei pazienti schizofrenici gravemente malati che non rispondono adeguatamente al trattamento farmaco standard per la schizofrenia
Lepotex Farmacologia
Clozapina è un agente psicotrope appartenente alla classe chimica dei derivati benzisossazolico ed è indicato per il trattamento della schizofrenia. Clozapina è un antagonista selettivo monoaminergico con alta affinità per il tipo di serotonina 2 (5HT2), tipo dopamina 2 (D2), 1 e 2 adrenergici e recettori H1 istaminergici. Clozapina agisce come un antagonista dei recettori, ma con minore potenza. Antagonismo in altri recettori di dopamina e 5HT2 con affinità simili potrebbero spiegare alcuni degli altri effetti terapeutici e collaterali della Clozapina. Antagonismo Clozapina di muscarinici M1-5 recettori possono spiegare i suoi effetti anticolinergici. Antagonismo Clozapina di recettori H1 dell'istamina possono spiegare la sonnolenza osservata con questo farmaco. Antagonismo Clozapina di recettori adrenergici a1 può spiegare l' ipotensione ortostatica osservato con questo farmaco.
Lepotex Assorbimento
Rapido e quasi completo
Lepotex Tossicita
Nessuna informazione disponibile
Lepotex Informazioni paziente
PATIENT INFORMATION
� Patients who are to receive CLOZARIL should be warned about the significant risk of developing agranulocytosis. They should be informed that weekly blood tests are required for the first 6 months, if acceptable WBC counts (WBC � 3000/mm3, ANC � 1500/mm3) have been maintained during the first 6 months of continuous therapy, then WBC counts can be monitored every other week in order to monitor for the occurrence of agranulocytosis, and that CLOZARIL tablets will be made available only through a special program designed to ensure the required blood monitoring. Patients should be advised to report immediately the appearance of lethargy, weakness, fever, sore throat, malaise, mucous membrane ulceration or other possible signs of infection.
Particular attention should be paid to any flu-like complaints or other symptoms that might suggest infection.
� Patients should be informed of the significant risk of seizure during CLOZARIL treatment, and they should be advised to avoid driving and any other potentially hazardous activity while taking CLOZARIL.
� Patients should be advised of the risk of orthostatic hypotension, especially during the period of initial dose titration.
� Patients should be informed that if they stop taking CLOZARIL for more than 2 days, they should not restart their medication at the same dosage, but should contact their physician for dosing instructions.
� Patients should notify their physician if they are taking, or plan to take, any prescription or over-the-counter drugs or alcohol.
� Patients should notify their physician if they become pregnant or intend to become pregnant during therapy.
� Patients should not breast-feed an infant if they are taking CLOZARIL.
� Patients who are to receive CLOZARIL should be warned about the significant risk of developing agranulocytosis. They should be informed that weekly blood tests are required for the first 6 months, if acceptable WBC counts (WBC � 3000/mm3, ANC � 1500/mm3) have been maintained during the first 6 months of continuous therapy, then WBC counts can be monitored every other week in order to monitor for the occurrence of agranulocytosis, and that CLOZARIL tablets will be made available only through a special program designed to ensure the required blood monitoring. Patients should be advised to report immediately the appearance of lethargy, weakness, fever, sore throat, malaise, mucous membrane ulceration or other possible signs of infection.
Particular attention should be paid to any flu-like complaints or other symptoms that might suggest infection.
� Patients should be informed of the significant risk of seizure during CLOZARIL treatment, and they should be advised to avoid driving and any other potentially hazardous activity while taking CLOZARIL.
� Patients should be advised of the risk of orthostatic hypotension, especially during the period of initial dose titration.
� Patients should be informed that if they stop taking CLOZARIL for more than 2 days, they should not restart their medication at the same dosage, but should contact their physician for dosing instructions.
� Patients should notify their physician if they are taking, or plan to take, any prescription or over-the-counter drugs or alcohol.
� Patients should notify their physician if they become pregnant or intend to become pregnant during therapy.
� Patients should not breast-feed an infant if they are taking CLOZARIL.
Lepotex Atto interessato organismi
Gli esseri umani e altri mammiferi
